Curcuminoids from Curcuma longaL. reduced intestinal mucositis induced by 5-fluorouracil in mice: Bioadhesive, proliferative, anti-inflammatory and antioxidant effects  by dos Santos Filho, Edvande Xavier et al.
C
i
a
E
C
R
M
a
b
c
a
A
R
R
A
A
K
M
C
C
I
5
1
b
c
G
B
h
2
nToxicology Reports 3 (2016) 55–62
Contents lists available at ScienceDirect
Toxicology  Reports
j ourna l ho me  page: www.elsev ier .com/ locate / toxrep
urcuminoids  from  Curcuma  longaL. reduced  intestinal  mucositis
nduced  by  5-ﬂuorouracil  in  mice:  Bioadhesive,  proliferative,
nti-inﬂammatory  and  antioxidant  effects
dvande  Xavier  dos  Santos  Filhoa, Paulo  Henrique  Marcelino  Ávilaa,
arla  Caroline  Cunha  Bastosa, Aline  Carvalho  Batistab, Letícia  Nasser  Navesc,
icardo  Neves  Marretoc, Eliana  Martins  Limac, Elismauro  Frascisco  Mendonc¸ ab,
arize Campos  Valadaresa,∗
Laboratory of Pharmacology and Cellular Toxicology, Pharmacy Faculty, Federal University of Goiás, Goiânia, Brazil
Department of Stomatology, Dental Faculty, Federal University of Goiás, Goiânia, Brazil
Laboratory of Pharmaceutical Technology, Pharmacy Faculty, Federal University of Goiás, Goiânia, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 20 August 2015
eceived in revised form 15 October 2015
ccepted 16 October 2015
vailable online 23 October 2015
eywords:
ucoadhesive formulation
urcuminoids
urcuma longa L
ntestinal mucositis
-Fluorouracil
a  b  s  t  r  a  c  t
Introduction:  Intestinal  mucositis  is a frequent  limiting  factor  in  anticancer  therapy  and there  is  currently
no broadly  effective  treatment  targeted  to cure  this  side  effect.
Objective:  This  study  aimed  to  evaluate  the  effects  of a mucoadhesive  formulation  containing  curcum-
inoids  (MFC)  from  Curcuma  longa  L. on the  pathogenesis  of 5-ﬂuorouracil  (5-FU)-induced  intestinal
mucositis.
Methods:  Three  intraperitoneal  5-FU  injections  (200  mg/kg)  were  used  to induce  intestinal  mucositis  in
adult  Swiss  male  mice.  Treatment  was  provided  orally  (MFC  3.75,  7.5  and  15  mg/kg),  thirty  minutes  before
5-FU  injections,  daily  until  euthanasia.  Duodenal  samples  were  collected  to  perform  morphometric  and
histopathological  analysis,  to investigate  the  expression  of  Ki-67,  p53,  Bax  and  Bcl-2  by  immunohis-
tochemistry,  to evaluate  neutrophil  activity  myeloperoxidase  (MPO)-mediated  and  oxidative  stress  by
malondialdehyde  (MDA)  determination.  Mice  body  weight  was  assessed  as  well.
Results:  As  expected,  5-FU  induced  a signiﬁcant  weight  loss  (∼17%,  P < 0.001),  shortening  in villi height
(∼55.4%)  and  crypts  depth  (∼47%),  and  increased  (∼64%)  the  histological  severity  score  when  compared  to
other  groups  (P < 0.05).  These  pathological  changes  were  markedly  alleviated  by  the  three  MFC  treatment
doses  (P  < 0.05),  in  special  with  the  dose  MFC  15  mg/kg.  This  dose  also  stimulated  cell  proliferation  by
∼90%  in  the  epithelial  cells  lining  from  villi  and  crypts  (P < 0.05),  reduced  MPO  levels  and MDA  formation
by  60%  and  44%,  respectively  (P < 0.05).
Conclusions: Our  data  suggest  the  therapeutic  potential  of  the  formulation  for treating  intestinal  mucositis
in  mice.  Supplementary  studies  are  underway  searching  for the  elucidation  of  mechanisms  involved  in
the protective  effects  of  MFC in  order  to make  this  formulation  a clinical  tool  for  mucositis  treatment.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. IntroductionThe clinical term mucositis describes a syndrome characterized
y ulceration in the entire gastrointestinal tract mucosa and asso-
iated symptoms [1]. The frequency of mucositis cases varies and is
∗ Corresponding author at: Faculdade de Farmácia – Universidade Federal de
oiás, Rua 240 esquina com 5a Avenida, s/n, Setor Universitário, Goiânia, Goiás,
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214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
inﬂuenced by factors such as patient’s diagnosis, age, health status,
and the type, dose and drug administration frequency [2].
It is very difﬁcult to thoroughly survey the occurrence of oral
and, in particular, intestinal mucositis induced by chemotherapy
and/or radiotherapy in humans. This is due to the fact that it is
not a locally mediated process but rather, a systemic one, with
concomitant oral lesions, emesis, anorexia, adynamia, abdominal
pain and, in particular, diarrhea [3]. 5-Fluorouracil, methotrexate
and other antimetabolite agents are the most established causes
of chemotherapy-induced mucositis. These agents attack tumor
cells and constantly dividing normal cell types, which result in
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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estruction of the basal cells and damage to connective tissue in
he gastrointestinal tract [1,2,4].
Even though scientists have been studying mucositis for over
hirty years [5], there is still no truly effective treatment tar-
eted to cure this side effect [2,6]. Current palliative treatments for
ntestinal mucositis include anti-inﬂammatories, systemic antibi-
tics, antidiarrheal medication and nonspeciﬁc painkillers [4,6,7].
hile no approach has yet standard gold proven efﬁcacy, numerous
gents are in used. Compounds such as growth factors (palifermin),
ree radical scavengers (amifostine), probiotics (Lactobacillus spp.),
inc sulphate, antioxidants (n-acetyl cysteine, l-glutamine), ben-
ydamine hydrochloride and coating agents (CAM2028, Gelclair,
uGard) have been tested with proved efﬁcacy [4–9].
Herbal products, particularly those with anti-inﬂammatory
nd antioxidant activities such as acteoside [10], iberogast
11],Chimonanthus nitens var. salicifolius [12], Bidens pilosa L. [13]
nd Rhodiola algida [14] are promising for the treatment of the
ucositis. Curcuma longa L. (also known as turmeric), belongs to
he ginger family (Zingiberaceae) and is traditionally used in cook-
ng for ﬂavoring purposes [15]. The anti-inﬂammatory, antioxidant
nd antitumor properties of C. longa L. constituents spurred the
nvestigation of the molecular mechanisms associated with these
iological activities [15,16]. This is a chemically diverse herb and
p until 2011, approximately 235 chemical compounds, mainly
henolic and terpenoid, have been identiﬁed [17].
It has been shown that formulations containing mucoadhe-
ive polymers, such as poloxamer 407, have the potential to treat
ucositis [4,6,13]. Mucoadhesive systems interact with mucin that
overs mucosa, thereby promoting prolonged and localized con-
act between the pharmaceutical dosage form and absorptive tissue
18].
Given the above, a mucoadhesive liquid formulation based on
oloxamer 407 and curcuminoids from C. longa L. was  developed to
mprove curcuminoids solubility and to promote intimate contact
etween the herbal active ingredients and gastrointestinal mucosa.
his formulation is hypothesized to be effective in treating mice
earing 5-FU-induced intestinal mucositis.
. Material and methods
.1. Mucoadhesive formulation containing curcuminoids (MFC)
MFC  was prepared by mixing polyethylene glycol 400 and
ropilenglycol (1:1, v/v) in a heated reactor (65–70 ◦C). Then, 9.0%
w/v) poloxamer 407 (Basf, Ludwigshafen, Germany) was  added to
he mixture under mechanical stirring until complete dispersion.
fter that, curcuminoids from C. longa L. extract (>95% curcumi-
oid content, Gamma  Comércio Importac¸ ão & Exportac¸ ão LTDA,
ão Paulo, Brazil) was added to the organic phase and pH was
djusted by using 0.1 M citric acid (pH 6.5). The ﬁnal concentration
f curcuminoids was 25 mg/mL. An aqueous fraction was  prepared
y dispersing 6% (w/v) of poloxamer 407 in puriﬁed water, under
onstant stirring. After dispersion, Soluplus® (Basf, Ludwigshafen,
ermany), sodium metabisulphite and sodium bisulphite were
dded under stirring. The aqueous fraction was then heated up to
5 ◦C and poured into organic fraction. The mixture was stirred for
0 min. MFC  was  then bottled in ambar ﬂask and stored at room
emperature until use. A blank mucoadhesive formulation (control)
as prepared as described above, but without adding curcuminoids
xtract..2. Mice
Swiss (8–10-week-old) male albino mice provided by our Insti-
ute’s Central Bioterium were kept under controlled temperatureogy Reports 3 (2016) 55–62
(25 ± 2 ◦C) and light conditions (12h-light–dark cycle), with free
access to water and standard chow pellets (Presence nutric¸ ão ani-
mal, São Paulo, Brazil). Mice were acclimatized for a week before
beginning the experiments. All animal treatment and surgical pro-
cedures were carried out in accordance with the norms of the
Brazilian College of Animal Experimentation (COBEA) and approved
by the local Research Ethics Committee (Federal University of Goiás
036/2012).
2.3. Experimental design
Considering that the 5-FU regime was  able to induce mucosi-
tis homogeneously in the mice, as well as ethical aspects in the
use of animals, three independent essays were performed with
mice randomly allocated into ﬁve experimental groups (Fig. 1) of
5 animals each. Groups were as follow: negative control (blank
mucoadhesive formulation 0.6 mL/animal, via gavage, from day
1–6); positive control (5-FU 200 mg/kg, i.p., days 4–6); and treated
(MFC 3.75 mg/kg; 7.5 mg/kg and 15 mg/kg, via gavage, from day
1–6). 5-FU (Sigma–Aldrich, St. Louis, USA) was diluted in sterile
water and injected intraperitoneally (i.p.), daily, for 3 consecutive
(days 4, 5 and 6) days into mice to induce mucositis. During the
induction of mucositis, MFC  treatment was given thirty minutes
before 5-FU injections, daily throughout the trial to the respective
groups via gavage. On the 7th day of the experiment, animals were
anesthetized by 10 mg/kg of xylazine and 100 mg/kg of ketamine
hydrochloride administered i.p. and euthanized by cervical dislo-
cation [19]. Duodenal samples, 10 cm after pyloric sphincter were
removed to perform the assays.
2.4. Body weight assessment
Mice were daily weighed throughout the entire experimental
period (7 days). The values were expressed as weight variation (%)
in relation to the weight at the beginning of the experimental period
[13].
2.5. Morphometric and histopathological analysis
Duodenal samples were ﬁxed in 10% phosphate buffered forma-
lin, embedded in parafﬁn, sectioned at 5 m thickness (Leica RM
2155, Heidelberg, Germany) and stained by hematoxylin and eosin
(H&E). For intestinal morphometric examination, villus height
(estimated from top of the villus to crypt-villus junction) and crypt
depth (deﬁned as adjacent intussusception) were determined using
the AxioVision 40 software (Carl Zeiss, Jena, Germany) and a light
microscope (Axio Scope A1Carl Zeiss, Jena, Germany) at 20X and
40X objectives. In this triple-blinded trial, ten villi and crypts from
each animal duodenal slide were measured and averaged for each
group.
Histopathological analysis evaluated the severity of intestinal
tissue damage caused by 5-FU using ten different histological
parameters, which consisted in villi and crypts size reduction, villi
and crypts disruptions and abscess formation, muscularis thicken-
ing, epithelium and muscular layer integrity, inﬂammatory cells
inﬁltration, vacuolization and mucosal edema. For each score, a
value of 0–3 was  given and combined for an overall score [10,13].
2.6. Immunohistochemistry for Ki-67, p53, Bax and Bcl-2
Duodenal samples were embedded in parafﬁn, sectioned
at 3 m thickness (Leica RM 2155, Heidelberg, Germany)
and mounted on silane-coated slides. The slides were then
deparafﬁnized, rehydrated in graded ethanol and washed with
tris-buffered saline (TBS) (pH 7.4). This was followed by incuba-
tion in a citric acid buffer solution (pH 6.0) at 96 ◦C for 20 min.
E.X. dos Santos Filho et al. / Toxicology Reports 3 (2016) 55–62 57
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sFig. 1. Schematic representation of MFC  trea
fterwards, slides were gradually cooled to room temperature and
ncubated in a 3% H2O2 solution for 30 min  to block endogenous
eroxidase activity. They were then incubated in bovine serum
lbumin (BSA 1%) for 20 min. The next step was overnight incu-
ation with one of the following primary antibodies (Santa Cruz
iotechnology, Santa Cruz, USA) at 4 ◦C: Ki-67 mouse monoclonal
gG1 (1:100); p53 mouse monoclonal IgG1 (1:50); Bax rabbit poly-
lonal IgG (1:50) and Bcl-2 mouse monoclonal IgG1 (1:50). After
hat, the streptavidin biotin peroxidase technique was performed.
lides were washed with TBS, incubated with secondary antibodies
ImmunoCruzTM mouse ABC staining systems sc-2017 or sc-2018,
anta Cruz Biotechnology, Santa Cruz, USA) for 30 min, washed
gain to eliminate excess free antibodies, incubated with reagent
nzyme (avidin + biotin HRP) and washed once more. Another incu-
ation was performed with streptavidin-peroxidase complex for
0 min  followed by a TBS wash. Finally, slides were incubated
n DAB developing solution (3.3’-diaminobenzidine) and counter-
ig. 2. Body weight variation in mice subjected to intestinal mucositis and treated
ith MFC  in relation to initial mass. Experiments performed in triplicate with 5
nimals per group. Mice were daily weighed throughout the experimental period
7  days). Data expressed as mean ± SEM. ***P < 0.001 comparing 5-FU vs Control;
P < 0.05 comparing 5-FU vs MFC  3.75 mg/kg + 5-FU; ##P < 0.001 comparing 5-FU vs
FC  7.5 mg/kg + 5-FU; and ###P < 0.001 comparing 5-FU vs MFC 15 mg/kg + 5-FU. For
tatistical analysis, one-way ANOVA and Bonferroni post-tests were applied. and intestinal mucositis induction by 5-FU.
stained with hematoxylin. The assays were performed in triplicate.
Negative controls were obtained by replacing primary antibodies
per 1% PBS–BSA.
Each slide was  analyzed and photographed using a light
microscopy (Axio Scope A1Carl Zeiss, Jena, Germany) at 40X objec-
tive. Also for each slide, a hundred duodenal epithelial cells were
counted in ten consecutive ﬁelds to determine the percentage of
positively stained cells expressing Ki-67, p53, Bax and Bcl-2.
2.7. Duodenal tissue homogenate preparation
Tissue homogenate procedure was carried out as previously
described by Ávila et al. [13]. Brieﬂy, 250 mg of duodenal tissue
from participants of each group were collected and homoge-
nized with hexadecyltrimethylammonium bromide buffer 0.5% by
a dispersing machine (T25-digital Ultra-Turrax®-IKA, Germany)
at 10.000 rpm, 25 ◦C for 5 min. Homogenates were centrifuged at
2000 rpm, 4 ◦C for 15 min, and supernatants obtained were used
for MPO  and MDA  analysis.
2.8. Myeloperoxidase (MPO) activity
MPO  activity assay was  performed by adding 10 L of samples
previously prepared to 96-well plastic plates (TPP, Trasadingen,
Switzerland), containing 100 L of phosphate buffered saline,
100 L of H2O2 0.1% and 50 L of orto-dianisidine 1.3%. The
absorbance reading was  performed at 450 nm wavelength. Results
were expressed as active MPO  unit per milligram of tissue [20].
2.9. Malondialdehyde (MDA) determination
Tissue MDA  determination was  carried out according to a modi-
ﬁed method developed by Ohkawa et al. [21]. Brieﬂy, 250 L of each
previously prepared supernatant sample was homogenized with
25 L of butylated hydroxytoluene 4%. Immediately afterwards,
1 mL  of trichloroacetic acid solution 12%, 1 mL of thiobarbituric
acid solution 0.73% and 750 L of tris–HCl buffer were added, and
the tubes were incubated at 95 ◦C water bath for 50 min. This mix-
ture was later homogenized with 1.5 mL of n-butanol, centrifuged
at 5000 rpm, 25 ◦C for 10 min, and supernatants were collected to
determine the absorbance at 532 nm wavelength.
5 oxicology Reports 3 (2016) 55–62
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Table 1
Histopathological severity scores of mice duodenum subjected to intestinal mucosi-
tis  and treated with MFC.
Groups Scores values
Control 3 (1, 5)
5-FU* 15 (9, 18)
MFC  3.75 mg/kg + 5-FU** 7 (3, 10)
MFC  7.5 mg/kg + 5-FU** 7 (3, 12)
MCF  15 mg/kg + 5-FU** 5 (2, 9)
Data expressed as median and range in parenthesis.
* P < 0.001 comparing 5-FU vs control.
**8 E.X. dos Santos Filho et al. / T
.10. Statistical analysis
Data are reported as means ± standard error of the mean. The
nter-group variation was evaluated by One- or Two-way Analysis
f Variance (ANOVA) followed by Bonferroni post-tests using the
indows version of GraphPad Prism 5.01 software (San Diego, CA,
SA). P–< 0.05 was considered statistically signiﬁcant.
. Results
.1. Effect of MFC  on animal body weight variation
Intestinal mucositis usually leads to decrease in food intake
nd absorption capacity, and body weight analysis is an objective
riterion for determining its severity [12,13]. As shown in Fig. 2,
ll groups gained body weight until the 4th day, with the excep-
ion of the control group that gained weight throughout the entire
xperimental period, reaching a peak of 14.5 ± 0.33%. From day 4,
nimals only exposed to 5-FU doses (200 mg/kg) showed signif-
cantly body weight loss (P < 0.001), reaching ∼17% reduction on
ay 7. In these animals, MFC  treatment attenuated 5-FU-induced
ody weight loss at all tested doses. Animals exposed to 5-FU and
reated with 3.75; 7.5 or 15 mg/kg of MFC  showed body weight of
0.2 ± 0.34%, 9.2 ± 0.28%, and 8.1 ± 0.3%, respectively.
ig. 3. Morphometric analysis of mice duodenum subjected to intestinal mucosi-
is  and treated with MFC. On day 7, duodenum segments were removed to
easure villus height (panel A) and crypt depth (panel B). Data expressed as
ean ± SEM. *P < 0.05 comparing 5-FU vs Control and #P < 0.05 comparing 5-FU vs
FC  3.75 mg/kg + 5-FU, MFC  7.5 mg/kg + 5-FU, MFC  15 mg/kg + 5-FU. For statistical
nalysis, two-way ANOVA and Bonferroni post-tests were applied.P < 0.05 comparing 5-FU vs MFC  3.75 mg/kg + 5-FU, MFC  7.5 mg/kg + 5-FU, and
MFC  15 mg/kg + 5-FU. For statistical analysis, one-way ANOVA and Bonferroni post-
tests  were applied.
3.2. Protective effect of MFC on 5-FU-induced intestinal mucositis
It is know that the reduction of intestinal length is a direct indi-
cator of intestinal damage induced by chemotherapy drugs such
as 5-FU and methotrexate [4–6,10–13]. Therefore, lengths of duo-
denal villi and crypts with different doses of MFC  treatment were
determined. As shown in Fig. 3A and B, 100% of animals exposed
to 5-FU showed a signiﬁcant shortening in villi height (∼55.4%)
and crypts depth (∼47%) when compared to control (P < 0.05). This
reduction was  markedly alleviated by the three MFC  treatment
doses (P < 0.05), with special emphasis on the MFC  15 mg/kg. These
results suggested that the 5-FU-induced duodenal mucositis could
be prevented and/ or reduced by MFC.
Furthermore, 5-FU group had a signiﬁcantly increased (∼64%)
histological severity score when compared to all other groups, char-
acterized by villi and crypts disruption and shortening, intense
inﬂammatory inﬁltration, vacuolization and mucosal edema (Fig. 4;
Table 1). Histological severity scores were signiﬁcantly (P < 0.05)
decreased in MFC  treated groups, especially MFC  15 mg/kg, except
for those related to inﬂammatory inﬁltration.
In view of these analyses, MFC  15 mg/kg demonstrated the most
effective results in treating intestinal mucositis and was then cho-
sen for subsequent investigations.
3.3. Effect of MFC on immunohistochemical detection of Ki-67,
p53, Bax and Bcl-2
Chemotherapy-induced mucositis is able to lead intestinal basal
stem cell to apoptosis, due its toxicity to the cellular turnover in
bowel tissue. Proteins of the Bcl-2 family play a central role in the
execution-phase of cell apoptosis together with p53 [3,33]. The pat-
tern of positive immunoexpression shown in Fig. 5 demonstrates an
increased expression of pro-apoptotic members p53, Bax and the
anti-apoptotic member Bcl-2 in 5-FU photomicrographs (P < 0.05).
Such high expression was  not observed among treated animals
(MFC 15 mg/kg), indicating less apoptosis (Fig. 6).
Cell proliferation is usually described in the healing stage of
chemotherapy-induced mucositis [1,2,4,6]. As expected, the Ki-
67 level in 5-FU mice decreased by ∼90% compared to control
(P < 0.05), and treatment with MFC  at 15 mg/kg induced greater
expression of Ki-67 protein (P < 0.05), shown by strong nuclear
staining on the epithelium of villi and crypts, which indicates cel-
lular proliferation (Fig. 5).
3.4. Effect of MFC in MPO  activity and MDA formation
MPO  is the most abundant enzyme present in azurophilic gran-
ules in neutrophils [20]. It is widely used as a neutrophil marker in
inﬂamed tissue such as mucositis [10,13,22]. MPO activity in duo-
denal tissue of 5-FU-induced mucositis group was by 70% higher
than in the control, and 60% higher relative to the treated group
E.X. dos Santos Filho et al. / Toxicol
Fig. 4. Histological sections of mice duodenum subjected to intestinal mucositis
and treated with MFC. Control (panels A and B) showing normal villi and crypts. 5-
FU (panels C and D) showing villi shortening (arrows), crypts deepening, intense
inﬂammatory inﬁltration, vacuolization and mucosal edema (arrowheads). MFC
3.75 mg/kg + 5-FU (panels E and F), MFC  7.5 mg/kg + 5-FU (panels G and H), MFC
15  mg/kg + 5-FU (panels I and J) showing villi and crypts preserved – both in size and
integrity –, however, inﬂammatory inﬁltrate was observed. H&E staining (panels A,
C,  E, G, I; 20X and B, D, F, H, J; 40X).ogy Reports 3 (2016) 55–62 59
(Fig. 5A, both P < 0.05). Additionally, there was no signiﬁcant differ-
ence between treated (MFC 15 mg/kg) and control group (P < 0.05).
MDA  is one of the ﬁnal products widely adopted for a sensitive
assay of lipid peroxidation and oxidative stress induced by ROS
in intestinal tissue [13,23,24]. Fig. 5B demonstrates there was an
increase by ∼51% in MDA  formation when mice which received
5-FU were compared to control group (P < 0.05). Treatment with
MFC  15 mg/kg signiﬁcantly reduced tissue oxidative stress and free
radical production in about 44% (P < 0.05). Likewise, in MDA  forma-
tion assay, there was no signiﬁcant difference between treated and
control group (P < 0.05).
4. Discussion
As no broadly curative drug treatment for mucositis is com-
mercially available, palliative procedures have been employed to
alleviate its signs and symptoms [25–28]. For its intestinal man-
ifestation, therapeutic and/or preventive approaches are applied
for infection and pain control, induction of cell proliferation and
reepithelialization [4,6–9]. Considering the range of cancers and
the occurrence of intestinal mucositis by antineoplastic agents, it
is necessary to search for therapeutic alternatives to alleviate this
serious side effect. In this study, MFC  exerted protective action
against 5-FU-induced morphological and histological intestinal
changes, especially at the dose of 15 mg/kg. Such effectiveness is
demonstrated by other anti-mucositis approaches [10–13,29,30].
Body weight analysis showed that MFC  was  capable of attenu-
ating weight loss induced by 5-FU. Intestinal mucositis generated
by chemotherapy potentially causes a decrease in food intake,
which linked to a loss in intestinal absorptive capacity lead to diar-
rheal episodes and body mass loss [1,3]. Diarrhea is reported as
high as 50–80% in patients undergoing chemotherapy, and tends
to become a limiting factor when severe [31]. Our data suggested
improvements in food intake and nutrition in mice bearing mucosi-
tis treated with MFC. This result is consistent with other proposed
experimental treatments for mucositis [10–14,32].
The occurrence of intestinal mucositis induced by chemother-
apy is directly associated with decreased cell proliferation and
increased apoptosis activity in mucosal epithelial cells and, con-
sequently, the modulation of regulatory proteins, such as the Bcl-2
family [33]. In this context, the tumor suppressor gene p53 interacts
with members of the Bcl-2 family in the mitochondrial membrane
promoting the release of cytochrome c, thereby increasing the tran-
scription of the Fas death receptor gene and inhibiting the secretion
of growth factors during chemotherapy sections [3,33].
To elucidate the inﬂuence of MFC  in cell proliferation/apoptosis
activity in mucosal epithelial cells of mice bearing mice, an
immunohistochemical identiﬁcation of proteins Ki-67, p53, Bax
and Bcl-2 was performed. Treatment with MFC  15 mg/kg induced a
slightly greater increase in the expression of Bcl-2 (anti-apoptotic)
than in Bax (pro-apoptotic) in the epithelium of villi and crypts.
Likewise, treatment discretely reduced p53 expression in the
animal mucosa. On the other hand, Ki-67 protein increased approx-
imately 90% of expression in villi and crypts epithelium duodenal,
when compared to 5-FU group, which indicates that the formu-
lation acted on the rate of intestinal cell proliferation. Recently,
Reinke et al. [10], Wright et al. [11], Ávila et al. [13], and Al-
Refai [34], also found that antineoplastic agents administration
result in increased apoptosis and decreased cellularity in the small-
intestinal mucosa. Like our ﬁndings, the imbalance of the rate cell
proliferation observed by these authors was modulated by the
treatment.
With a view to measuring neutrophil inﬁltration in duodenal
tissue, intestinal MPO  activity was  investigated. MPO  levels were
increased in duodenal tissue of 5-FU group, when compared to con-
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rol. Otherwise, MPO  amount in duodenal segments of mice treated
ith MFC  was almost equivalent of normal levels, indicating less
eutrophil inﬁltration and consequently less inﬂammation. Our
ata is consistent with the ﬁndings of Reinke et al. [10] and Ferreira
t al. [32].
ig. 5. Expression of Ki-67 (cell proliferation), p53 (pro-apoptotic), Bax (pro-apoptotic) an
ee  black arrows. Immunohistochemical staining, original magniﬁcation, 40X. Data expre
s  MFC  15 mg/kg. For statistical analysis, two-way ANOVA and Bonferroni post-tests werogy Reports 3 (2016) 55–62
MDA  quantiﬁcation has been used as a marker for the produc-
tion of reactive oxygen species (ROS). ROS are involved in numerous
mechanisms of injury, and one of the most signiﬁcant is lipid per-
oxidation present in cell membranes. In this analysis, we measured
lipid peroxidation associated to oxidative stress through the pro-
duction of MDA  in duodenal tissue samples. MDA  values found
d Bcl-2 (anti-apoptotic) in mice bearing intestinal mucositis and treated with MFC.
ssed as mean ± SEM. *P < 0.05 comparing 5-FU vs Control, #P < 0.05 comparing 5-FU
e applied.
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n mice bearing mucositis and treated with MFC  were about 50%
ower than the values of 5-FU group, and equivalent to those of
he control group. Our data correlates to Marques et al. [35] and
unha et al. [36]. Thus, considering MDA  levels found, it is sug-
ested that 5-FU acted as a pro-oxidant on intestinal epithelium by
eeping mucosa under constant oxidative damage. Furthermore,
e propose that MFC  was capable of protecting this epithelium,
hrough the antioxidant properties of curcuminoids and mucoad-
esive physical protection effect of poloxamer 407.
Mucoadhesive formulations allow intimate contact between the
harmaceutical form and the absorbing membrane by creating a
lm on the mucus layer lining of mucosa, thereby reducing its
pread and protecting the drug from possible degradation in the
ntestinal lumen [37]. Therefore, the beneﬁt rendered by mucoad-
esive formulations would be a once daily regime, which would
mprove treatment compliance and reduce adverse effects [38].
hen et al. [39] evaluated the potential of Poloxamer 407 as a
hermogelling mucoadhesive polymer to improve curcuminoids
ioavailability in primary culture cells. Their results revealed con-
rolled curcuminoid release over a 24 h period. In our study, it can
uggest that the components of mucoadhesive formulation acted as
ehicle for curcuminoids and probably increased the contact time
etween extract components and intestinal mucosa.
In different parts of the world, the dry extract obtained from
. longa L. has been used for centuries associated with numerous
iological activities [15]. However, as unformulated curcuminoids
ave relatively low bioavailability and poor aqueous solubility
16,40]. Yang et al. [41] observed that intestinal absorption of cur-
uminoids in murine models is only around 60%. Thus, our data
urther emphasizes the importance of the mucoadhesive formula-
ion in reaching the expected clinical outcome against mucositis.
A study conducted by Henrotin et al. [42] demonstrated that
here are many molecular evidences to justify the potential of C.
onga L. components (monoterpenes, diterpenes, sesquiterpenes)
or the treatment of various inﬂammatory diseases. However, in
nimal bearing mucositis and treated with MFC  we still observed
nﬂammatory inﬁltrate, which could be attributed to the presence
f other inﬂammatory cells than neutrophils, such as lymphocyte
nﬁltration.
Our data demonstrate that MFC  exerted protective action
gainst duodenal mucosa damage caused by 5-FU. It also stimu-
ated cell proliferation, reduced weight loss, MPO  levels and MDA
ormation. Supplementary studies are underway searching for the
lucidation of mechanisms involved in the protective effects of MFC
n order to make this formulation a clinical tool for the prevention
nd/or treatment of mucositis.
[ions of mice bearing intestinal mucositis. Experiments performed in triplicate with
P < 0.05 comparing 5-FU vs MFC  15 mg/kg. For statistical analysis, one-way ANOVA
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